Skip to main content
SpringerLink
Log in

Progress in the Development Of Natural Products for Human Immunodeficiency Viruses Infections

  • Chapter
Natural Products as Antiviral Agents

Abstract

Diverse antiviral compounds are needed to meet the challenge of infections caused by viruses responsible for high morbidity and/or mortality. These viruses include human immunodeficiency viruses (HIV-1; HIV), herpesviruses, hepatitis B virus, influenza viruses, and exotic viruses. Certain antiviral compounds have been successfully derived from a variety of natural products whose structure and composition could not have been predicted by even the most imaginative of chemists. The selectivity of these antiviral agents hinges upon unique biochemical events specific for viral replication but not cellular growth. Inhibition of viral specific receptors on cells also represents an attractive target. This review addresses some of these approaches with emphasis on the potential role of natural products in treating HIV infections.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 99.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. P.S. Rosenberg, M.H. Gail, L.K. Schrager, et al, National AIDS incidence trends and the extent of zidovudine therapy in selected demographic and transmission groups., J. Acquir. Immun. Defic. Syndr. 4:392 (1991).

    CAS  Google Scholar 

  2. W.A. Haseltine, Development of antiviral drugs for the treatment of AIDS: Strategies and prospects, J. Acquir. Immun. Defic. Syndr. 2:311 (1989).

    CAS  Google Scholar 

  3. W.A. Haseltine, Molecular biology of the human immunodeficiency virus type 1, FASEB J. 5:2349 (1991).

    PubMed  CAS  Google Scholar 

  4. H. Mitsuya, R. Yarchoan, S. Kageyama, S. Broder, Targeted therapy of human immunodeficiency virus-related disease, FASEB. 5:2369 (1991).

    CAS  Google Scholar 

  5. J.P. Moore, J.A. McKeating, Weiss RA, Q.J. Sattentau, Dissociation of gp120 from HIV-1 virions induced by soluble CD4, Science 250:1139 (1990).

    Article  PubMed  CAS  Google Scholar 

  6. J.P. Moore, J.A. McKeating, W.A. Norton, Q.J. Sattentau, Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4, J. Virol. 65(3): 1133 (1991).

    PubMed  CAS  Google Scholar 

  7. R.H.R. Ward, D.J. Capon, C.M. Jett, et al., Prevention of HIV-1 IIIB infection in chimpanzees by CD4 immunoadhesin, Nature 352:434 (1991).

    Article  PubMed  CAS  Google Scholar 

  8. J.W. Mellors, G.E. Dutchman, J-J Im, E. Tramontano, S.R. Winkelr, Y-C Cheng, In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase, Mol. Pharmac. 41:446 (1992).

    CAS  Google Scholar 

  9. D. Richman, C-K Shih, I. Lowy, et al., HIV-1 mutants resistant to non-nucleosides inhibitors of reverse transcriptase arise in tissue culture, Proc. Natl. Acad. Sci. USA, 88:11241 (1991).

    Article  PubMed  CAS  Google Scholar 

  10. S.E. Krown, F.X. Real, S. Cunningham-Rundles, et al., Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi’s sarcoma, N. Engl. J. Med. 308:1071 (1983).

    Article  PubMed  CAS  Google Scholar 

  11. S. Krown, AIDS-associated Kaposi’s sarcoma: Pathogenesis, clinical course and treatment, AIDS 2:71 (1988).

    Article  PubMed  CAS  Google Scholar 

  12. D.D. Ho, K.L. Hartshorn, T.R. Rota, et al., Recombinant human interferon alpha-A suppresses HTLV-III replication in vitro, Lancet 1:602 (1985).

    Article  PubMed  CAS  Google Scholar 

  13. R. de Wit, J.K. Schattenkerk, C.A. Boucher, P.J. Bakker, K.H. Veenhof, S.A. Danner, Clinicl and virological effects of high-dose recombinant interferon-α in disseminated AIDS-related Kaposi’s sarcoma, Lancet 2:1214 (1988).

    Article  PubMed  Google Scholar 

  14. H.C. Lane, J.A. Kovacs, J. Feinberg, et al., Anti-retroviral effects of interferon-α in AIDS-associated Kaposi’s sarcoma, Lancet 2:1218 (1988).

    Article  PubMed  CAS  Google Scholar 

  15. V. Davey, J.A. Kovacs, B. Herpin, J.A. Metcalf, A.S. Fauci, H.C Lane, A placebo controlled trial of interferon alpha-2b in asymptomatic HIV infection, V International Conference on AIDS, Montreal (1989).

    Google Scholar 

  16. G.H. Friedland, R.S. Klein, B.R. Saltzman, et. al., A randomized placebo-controlled trial of recombinant human interferon alpha 2a in patients with AIDS, J. Acquir. Immun. Defic.Syndr. 1:111 (1988).

    Google Scholar 

  17. K.L. Hartshorn, D. Neumeyer, M.W. Vogt, R.T. Schooley, M.S. Hirsch, Activity of interferons alpha, beta, and gamma against human immunodeficiency virus replication in vitro, AIDS Res. Human Retrov. 3:125 (1987).

    Article  CAS  Google Scholar 

  18. P.M. Pitha, J.A. Bilello, C.H. Riggin, Effect of interferon on retrovirus replication, Texas Rep. Biol. Med. 41:603 (1981).

    CAS  Google Scholar 

  19. J.K. Yamamoto, F. Barre-Sinoussi, F. Bolton, N.C. Pedersen, M.B. Gardner, Human alpha and beta interferon but not gamma suppress the in vitro replication of LAV, HTLV-III and ARV-2, J. Interferon Res. 6:143 (1986).

    Article  PubMed  CAS  Google Scholar 

  20. Y. Yasuda, S. Miyake, S. Kato, et al., Interferon-a treatment leads to accululation of virus particles on the surface of cells persistently infected with the human immunodeficiency virus type 1, J. Acquir. Immun. Defic. Syndr. 3:1046 (1990).

    CAS  Google Scholar 

  21. M.S. Smith, R.J. Thresher, J.S. Pagano, Inhibition of human immunodeficiency virus type 1 morphogenesis in T cells by alpha interferon, Antimicrob. Agents Chemother. 35:62 (1991).

    Article  PubMed  CAS  Google Scholar 

  22. H.E. Geldenman, R. M. Friedman, S. Joe, et al., A selective defect of interferon alpha production in human immunodeficiency virus-infected monocytes, (published erratum appears in J. Exp. Med. 173:277 (1991), J. Exp. Med. 172:1433 (1990).

    Article  Google Scholar 

  23. H. Geldenman, L. Baca, J. Turpin, et al., Regulation of HIV replication in infected monocytes by INF-α, J. Immunol. 145:2669 (1990).

    Google Scholar 

  24. R.F. Schinazi. Combined therapeutic modalities for viruses: Rationale and clinical potential, in: “Molecular Mechanisms of Chemotherapeutic Synergism, Potentiation, and Antagonism,” T.C. Chou, D.C. Rideout, eds., Academic Press, Orlando, FL (1972).

    Google Scholar 

  25. J.A. Kovács, L. Deyton, R. Davey, et al., Combined zidovudine and interferon a therapy in patients with Kaposi’s sarcoma and the acquired immunodeficiency syndrome (AIDS), Ann. Intern. Med. 111:280 (1989).

    PubMed  Google Scholar 

  26. M.W. Vogt, A.G. Durno, T.C. Chou, et al., Synergistic interaction of 2′,3′-dideoxycytidine and recombinant interferon-α-A on replication of human immunodeficiency virus type 1, J. Infect. Dis. 158:378 (1988).

    Article  PubMed  CAS  Google Scholar 

  27. D.T. Scadden, H.A. Bering, J.D. Levine, et al., Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alpha and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi’s sarcoma, J. Clin. Oncol. 9:802 (1991).

    PubMed  CAS  Google Scholar 

  28. D.T. Scadden, H.A. Bering, J.D. Levine, et al., CM-CSF as an alternative to dose modification of the combination zidovudine and interferon-alpha in the treatment of AIDS-associated Kaposi’s sarcoma, Am J. Clin. Oncol. 14:S40 (1991).

    Article  PubMed  Google Scholar 

  29. R. Datema, S. Olofsson, P.A. Romero, Inhibitors of protein glycosylation and glycoprotein processing in viral systems, Pharmacol. Ther. 33:221 (1987).

    Article  PubMed  CAS  Google Scholar 

  30. R.M. Ruprecht, L.D. Bernard, R. Bronson, M.A. Gama Sosa, S. Millaney, Castanospermine vs. its 6-O-butanoyl analog: A comparison of toxicity and antiviral activity in vitro and in vivo, J. Acquir. Immun. Defic. Syndr. 4:48 (1991).

    CAS  Google Scholar 

  31. R.M. Ruprecht, Murine models for antiretroviral therapy, Intervirology 30:2 (1989).

    PubMed  Google Scholar 

  32. P.S. Sunkara, T.L. Bowlin, P.S. Liu, A. Sjoerdsma., Antiretroviral activity of castanospermine and deoxynojirimycin, specific inhibitors of glycoprotein processing, Biochem. Biophys. Res. Commun. 1:206 (1987).

    Article  Google Scholar 

  33. D. Schols, R. Pauwels, M. Witvrouw, J. Desmyter, E. De Clercq, Differential activity of polyanionic compounds and castanospermine against HIV replication and HIV-induced syncytium formation depending on virus strain and cell type, Antiviral Chem. Chemother. 3:23 (1992).

    CAS  Google Scholar 

  34. R.M. Ruprecht, S. Mullaney, J. Andersen, R. Bronson, In vivo analysis of castanospermine, a candidate antiretroviral agent, J. Acquir. Immun. Defic. Syndr. 2:149 (1989).

    CAS  Google Scholar 

  35. M.G. Hollingshead, L. Westbrook, B.J. Toyer, L.B. Allen, Failure of castanospermine to reduce spleen or serum virus titers in Rauscher murine leukaemia virus-infected mice, Antiviral Chem. Chemother. 2:119 (1991).

    CAS  Google Scholar 

  36. P.S. Sunkara, M.S. Kang, T.L. Bowlin, P.S. Liu, A.S. Tyms, A. Sjoerdsma, Inhibition of glycoprotein processing and HIV replication by castanospermine analogues, Ann. NY Acad. Sci. 616:90 (1990).

    Article  PubMed  CAS  Google Scholar 

  37. A. Karpas, G.W.J. Fleet, R.A. Dwek, et al., Aminosugar derivatives as potential anti-human immunodeficiency virus agents, Proc. Natl. Acad. Sci. USA 85:9229 (1988).

    Article  PubMed  CAS  Google Scholar 

  38. H. Shimizu, H. Tsuchie, K. Yoshida, et al., Inhibitory effect of novel 1-deoxynojirimycin derivatives on HIV-1 replication, AIDS 4:975 (1990).

    Article  PubMed  CAS  Google Scholar 

  39. I.M. Jones, G.S. Jacob, Anti-HIV drug mechanism, Nature 352:198 (1991)

    Article  PubMed  CAS  Google Scholar 

  40. R.F. Arakaki, J.A. Hedo, E. Collier, P. Gorden, Effects of castanospermine and 1-deoxynojirimycin on insulin receptor biogenesi: Evidence for a role of glucose removal from core oligosaccharides, J. Biol. Chem. 262:1186 (1987).

    Google Scholar 

  41. R. Saul, J.J. Ghidoni, R.J. Molyneux, A.D. Elbein, Castanospermine inhibits alpha-glucosidase activities and alters glycogen distribution in animals, Proc. Natl. Acad. Sci. USA 82:93 (1985).

    Article  PubMed  CAS  Google Scholar 

  42. V.A. Johnson, B.D. Walker, M.A. Barlow, T.J. Paradis, T-C Chou, M.S. Hirsch, Synergistic inhibition of human immunodeficiency virus type 1 and type 2 replication in vitro by castanospermine and 3′-azido-3′-deoxythymidine, Antimicrob. Agents Chemother. 33:53 (1989).

    Article  PubMed  CAS  Google Scholar 

  43. R.S. Chang, L. Ding, C. Gai-Qing, P. Qi-Choa, Z. Zi-Lin, K.M. Smith, Dehydroandrographolide succinic acid monoester as an inhibitor against the human immunodeficiency virus, Proc. Soc. Exp. Biol. Med. 197:59 (1991).

    PubMed  CAS  Google Scholar 

  44. S-Z Qian, Z-G Wang, Gossypol: A potential antifertility agent for males, Ann. Rev. Pharmacol. Toxicol. 24:329 (1984).

    Article  CAS  Google Scholar 

  45. E.E. Montamat, C. Burgos, N.M. Gerez de Burgos, L.E. Rovai, A. Blanco, E.L. Segura, Inhibitory action of gossypol on enzymes and growth of trypanosoma cruzi, Science 218:288 (1982).

    Article  PubMed  CAS  Google Scholar 

  46. J.E. Heidrich, L.A. Hunsaker, Gossypol, an antifertility agent, exhibits antimalarial activity in vitro, IRCS Med. Sci. 11:304 (1983).

    CAS  Google Scholar 

  47. P.H. Dorset, E.E. Kerstin, L.J. Powers, Antiviral activity of gossypol and apogossypol, J. Pharm. Sci. 64:1073 (1975).

    Article  Google Scholar 

  48. K. Wichmann, A. Vaheri, T, Luukkainen. Inhibiting herpes simplex virus type 2 infection in human epithelial cells by gossypol, a potent spermicidal and contraceptive agent, Amer. J. Obstet. Gynecol. 142:593 (1982).

    CAS  Google Scholar 

  49. B. Polsky, J.W.M. Gold, P.A. Baron, et al., Inactivation of human immunodeficiency virus (HIV) by gossypol (GP), Clin. Res. 35:487A (1987).

    Google Scholar 

  50. D.S. Sampath, P. Balaram, Resolution of racemic gossypol and interaction of individual enantiomers with serum albumens and model peptides, Biochem. Biophys. Acta 2:183 (1986).

    Google Scholar 

  51. T-S Lin, R.F. Schinazi, B.P. Griffith, et al., Selective inhibition of human immunodeficiency virus type 1 replication by the (-) but not the (+) enantiomer of gossypol, Antimicrob. Agents. Chemother. 33:2149 (1989).

    Article  PubMed  CAS  Google Scholar 

  52. D. Meruelo, G. Lavie, D. Lavie, Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: Aromatic polycyclic diones hypericin and pseudohypericin, Proc. Natl. Acad. Sci. USA 85:5230 (1988).

    Article  PubMed  CAS  Google Scholar 

  53. D. Meruelo, G. Lavie, Mechanisms of the antiretroviral activity of aromatic polycyclic diones hypericin and pseudohypericin, Int. Conf. AIDS 5:662 (1989).

    Google Scholar 

  54. I. Takahashi, S. Nakanishi, E. Kobayashi, H. Nakano, K. Suzuki, T. Tamaoki, Hypericin and pseudohypericin specifically inhibit protein kinase C: Possible relation to their antiretroviral activity, Biochem. Biophys. Res. Commun. 165:1207 (1989)

    Article  PubMed  CAS  Google Scholar 

  55. J. Tang, J.M. Colacino, S.H. Larsen, W. Spitzer, Virucidal activity of hypericin against enveloped and non-enveloped DNA and RNA viruses, Antiviral Res. 13:313 (1990).

    Article  PubMed  CAS  Google Scholar 

  56. G.A. Kraus, D. Pratt, J. Tossberg, S., Carpenter. Antiretroviral activity of synthetic hypericin and related analogs, Biochem. Biophys. Res. Commun. 172:149 (1990).

    Article  PubMed  CAS  Google Scholar 

  57. J.B. Hudson, I. Lopez-Bazzocchi, G.H.N. Towers, Antiviral activities of hypericin, Antiviral Res. 15:101 (1991).

    Article  PubMed  CAS  Google Scholar 

  58. D.O. Andersen, N.D. Weber, S.G. Wood, B.G. Hughes, B.K. Murray, J.A. North, In vitro virucidal activity of selected anthraquinones and anthraquinone derivatives, Antiviral Res. 16:185 (1991).

    Article  PubMed  CAS  Google Scholar 

  59. F.T. Valentine, V. Itri, N. Kudler, R. Georgescu, Synthetic hypericin enters blood lymphocytes and monocytes in vitro and decreases culturable HIV in blood obtained from infected individuals, VII International Conference on AIDS, Florence, 97 (1991).

    Google Scholar 

  60. Y. Hafuri, E. Takemori, K. Oogose, et al, Mechanism of inhibition of reverse transcriptase by quinone antibiotics II. Dependence on putative quinone pocket on the enzyme molecule, J. Antibiotics 41:1471 (1988).

    Article  CAS  Google Scholar 

  61. K.V.R. Dhananjaya, A. Antony, Inhibition of avian myeloblastosis virus reverse transcriptase and its associated activities by daunomycin and adriamycin, Ind. J. Biochem. Biophys. 24:265 (1987).

    CAS  Google Scholar 

  62. H. Nakashima, N. Yamamoto, Inhibition by doxorubicin of human immunodeficiency virus (HIV) infection and replication in vitro, J. Antibiotics 40:396 (1987).

    Article  CAS  Google Scholar 

  63. G. Lavie, F. Valentine, B. Levin, et al., Studies of the mechanisms of action of the antiretroviral agents hypericin and pseudohypericin, Proc. Natl. Acad. Sci. 86:5963 (1989).

    Article  PubMed  CAS  Google Scholar 

  64. R.F. Schinazi, C.K. Ch, J.R. Babu, et al., Anthraquinones as a new class of antiviral agents against human immunodeficiency virus, Antiviral Res. 13:265 (1990).

    Article  PubMed  CAS  Google Scholar 

  65. H. Higuchi, K. Mori, A. Kato, et al., Antiretroviral activities of anthraquinones and their inhibitory effects on reverse transcriptase, Antiviral Res. 15:205 (1991).

    Article  PubMed  CAS  Google Scholar 

  66. D.I. Abrams, Alternative therapies in HIV infection, AIDS 4:1179 (1990).

    Article  PubMed  CAS  Google Scholar 

  67. K.P. Manfredi, J.W. Blunt, J.H.I. Cardellina, et al., Novel alkaloids from the tropical plant Ancistrocladus abbreviatus inhibit cell killing by HIV-1 and HIV-2, J. Med. Chem. 34:3402 (1991).

    Article  PubMed  CAS  Google Scholar 

  68. E. Priel, S.D. Showalter, D.G. Blair, Inhibition of human immunodeficiency virus (HIV-1) replication in vitro by noncytotoxic doses of camptothecin, a topoisomerases I inhibitor, AIDS Res. Hum. Retrov. 7:65 (1991).

    CAS  Google Scholar 

  69. C. Schweitzer, F. Keller, M.P. Schmitt, et al., Morphine stimulates HIV replication in primary cultures of human Kupffer cells, Res. Virol. 142:189 (1991).

    Article  PubMed  CAS  Google Scholar 

  70. P.K. Lai, J. Donovan, H. Takayama, et al., Modification of human immunodeficiency viral replication by pine cone extracts, AIDS Res. Hum. Retrov. 6:205 (1990).

    Article  CAS  Google Scholar 

  71. H. Takayama, G. Bradley, P.K. Lai, et al., Inhibition of human immunodeficiency virus forward and reverse transcription by PC6, a natural product from cones of pine trees, AIDS Res. Hum. Retrov. 7:349 (1991).

    Article  CAS  Google Scholar 

  72. Y. Tamura, P.K. Lai, W.G. Bradley, K. Konno, A. Tanaka, M. Nonoyama, A soluble factor induced by an extract from Pinus parviflora Sieb et Zucc can inhibit the replication of human immunodeficiency virus in vitro, Proc. Natl. Acad. Scc. 88:2249 (1991).

    Article  CAS  Google Scholar 

  73. D.C. Montefiori, J. Zhou, Selective antiviral activity of synthetic soluble L-tyrosine and L-DOPA melanins against human immunodeficiency virus in vitro, Antiviral Res. 15:11 (1991).

    Article  PubMed  CAS  Google Scholar 

  74. M. Nishizawa, T. Yamagishi, G.E. Dutschman, et al., Anti-AIDS agents, 1. Isolation and characterization of four new tetragalloylquinic acids as a new class of HIV reverse transcriptase inhibitors from tannic acid, J. Nat. Prod. 52:762 (1989).

    Article  PubMed  CAS  Google Scholar 

  75. H.C. Schröder, H. Merz, R. Steffen, et al., Differential in vitro anti-HIV activity of natural lignans, Z. Naturforsch. (C)45:1215 (1990).

    Google Scholar 

  76. H. Nakashima, T. Murakami, N. Yamamoto, et al., Inhibition of human immunodeficiency viral replication by tannins and related compounds, Antiviral Res. 18:91 (1992).

    Article  PubMed  CAS  Google Scholar 

  77. W. Kreis W.M.H. Kaplan, J. Freeman, D.K. Sun, P.S. Sarin, Inhibition of HIV replication by Hyssop officinalis extracts, Antiviral Res. 14:323 (1990).

    Article  PubMed  CAS  Google Scholar 

  78. R.F. Schinazi. Antiviral activity of dehydroepiandrosterone, in: “The biological role of dehydroepiandrosterone (DHEA),” M. Kalimi, W. Regelson, eds, Walter de Gruyter & Co, New York (1990).

    Google Scholar 

  79. J.M. Laurence, B. Sellers, S.K. Sikder, Effect of glucocorticoids on chronic human immunodeficiency virus (HIV) infection and HIV promoter-mediated transcription, Blood 14:291 (1989).

    Google Scholar 

  80. M.S. McGrath, S. Santulli, I. Gaston, Effects of GLQ223(tm) on HIV replication in human monocyte/macrophages chronically infected in vitro with HIV, AIDS Res. Hum. Retrov. 6:1039 (1990).

    CAS  Google Scholar 

  81. P. Ferrari, M. Trabaud, M. Rommain, et al., Toxicity and activity of purified trichosanthin, AIDS 5:865 (1991).

    Article  PubMed  CAS  Google Scholar 

  82. V.S. Byers, A.S. Levin, L.A. Waites, et al., A phase I/II study of trichosanthin treatment of HIV disease, AIDS 4:1189 (1990).

    Article  PubMed  CAS  Google Scholar 

  83. J.O. Kahn, L.D. Kaplan, J.G. Gambertogilo, et al., The safety and pharmacokinetics of GLQ223 in subjects with AIDS and ABDS-related complex: A Phase I study, AIDS 4:1197 (1990).

    Article  PubMed  CAS  Google Scholar 

  84. J. Palaca, Trials and tribulations of AIDS testing, Science 247:14406 (1990).

    Google Scholar 

  85. S. Lee-Huang, P.L. Huang, P.L. Nara, et al., MAP 30: A new inhibitor of HIV-1 infection and replication, FEBS Lett. 272:12 (1990).

    Article  PubMed  CAS  Google Scholar 

  86. 81a. M.C. Olson, S. Ramakrishnan, Anand R, Ribosomal inhibitory proteins from plants inhibit HIV-1 replication in acutely infected peripheral blood mononuclear cells, AIDS Res Hum Retrovir 7:1025 (1991).

    Article  PubMed  CAS  Google Scholar 

  87. S. Lee-Huang, P.L. Huang, H-F. Kung, et al., TAP 29: An anti-human immunodeficiency virus protein from Trichosanthes kirilowii that is nontoxic to intact cells, Proc. Natl. Acad. Sci. 88:6570 (1991).

    Article  PubMed  CAS  Google Scholar 

  88. S Lee-Huang, H-F Kung, P.L. Huang, et al., A new class of anti-HIV agents: GAP 31, DAPs 30 and 32, FEBS Lett. 291(1):139 (1991).

    Article  PubMed  CAS  Google Scholar 

  89. D.W. Dixon, M.S. Kim, V. Kumar, G. Obara, L. Marzilli, R.F. Schinazi, Structure-activity relationship of amino and hydroxytetraphenylporphyrin derivatives with anti-HIV activity, Antiviral Chem. Chemother., in press (1992).

    Google Scholar 

  90. D.W. Dixon, R.F. Schinazi, L.G. Marzilli, Porphyrins as agents against the human immunodeficiency virus, Ann NY Acad. Sci. 616:511 (1990).

    Article  Google Scholar 

  91. B.R. Munson, R.J. Fiel, Hematoporphyrin-sensitized photodynamic inactivation of viral RNA-dependent DNA polymerase, Res. Commun. Chem. Pathol. Pharmacol. 16:175 (1977).

    PubMed  CAS  Google Scholar 

  92. K. Tsutsui, G.C. Mueller, Hemin inhibits virion-associated reverse transcriptase of murine leukemia virus, Biochem. Biophys. Res. Comm. Pharmacol. 149:628 (1987).

    Article  CAS  Google Scholar 

  93. M. Asanaka, T. Kurimura, H. Toya, J. Ogaki, Y. Kato, Anti-HIV activity of protoporphyrin, AIDS 3:403 (1989).

    Article  PubMed  CAS  Google Scholar 

  94. R. Kuroda, E. Takahashi, C.A. Austin, L.M. Fisher, DNA binding and intercalation by novel porphyrins: Role of charge and substituents probed by DNase I footprinting and topoisomerase I unwinding, FEBS Lett. 262:293 (1990).

    Article  PubMed  CAS  Google Scholar 

  95. K. Boekelheide, J. Eveleth, A.H. Tatum, J.W. Winkelman, Microtubule assembly inhibition by porphyrins and related compounds, Photochem. Photobiol. 46:657 (1987).

    Article  PubMed  CAS  Google Scholar 

  96. A. Novogrodsky, M. Suthanthiran, K.H. Stenzel, Immune stimulatory properties of metalloporphyrins, J. Immunol. 143:3981 (1989).

    PubMed  CAS  Google Scholar 

  97. S.H. Snyder, A. Verma, R.R. Trifilietti, The peripheral-type benzodiazepine receptor: A protein of mitochondrial outer membranes utilizing porphyrins and endogenous ligands, FASEB 1:282 (1987).

    CAS  Google Scholar 

  98. K. Ikezaki, K. Black, Stimulation of cell growth and DNA synthesis by peripheral benzodiazepine, Cancer Lett. 49:115 (1990).

    Article  PubMed  CAS  Google Scholar 

  99. S.L. Gibson, R. Hilf, Interdependence of fluence, drug dose and oxygen on hematoporphyrin derivative induced photosensitization of tumor mitochondria, Photochem. Photobiol. 42:367 (1985).

    Article  PubMed  CAS  Google Scholar 

  100. S.L. Gibson, R. Hilf, Photosensitization of mitochondrial cytochrome c oxidase by hematoporphyrin derivative and related porphyrins in vitro and in vivo, Cancer Res. 43:4191 (1983).

    PubMed  CAS  Google Scholar 

  101. V.G. Schweitzer, D. Visscher, Photodynamic therapy for treatment of AIDS related oral Kaposi’s sarcoma, Otolaryngol. Head Neck Surg. 102:639 (1990).

    PubMed  CAS  Google Scholar 

  102. M. Baba, H. Tanaka, E. De Clercq, et al., Highly specific inhibition of human immunodeficiency virus type 1 by novel 6-substituted acyclouridine derivative, Biochem. Biophys. Res. Commun. 165:1375 (1989).

    Article  PubMed  CAS  Google Scholar 

  103. H. Mitsuya, D.J. Looney, S. Kuno, R. Ueno, F. Wong-Staal, S. Broder, Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells, Science 240:646 (1988).

    Article  PubMed  CAS  Google Scholar 

  104. T. Moriya, H. Kurita, K. Matsumoto, et al., Potent inhibitory effect of a series of modified cyclodextrin sulfates (mCDS) on the replication of HIV-1 in vitro, J. Med. Chem. 34:2301 (1991).

    Article  PubMed  CAS  Google Scholar 

  105. H. Nakashima, T. Matsui, O. Yoshida, et al., A new anti-human immunodeficiency virus substance, glycyrrhizin sulfate; endowment of glycyrrhizin with reverse transcriptase-inhibitory activity by chemical modification, Jpn. J. Cancer Res. (Gann)78:767 (1987).

    PubMed  CAS  Google Scholar 

  106. L.N. Callahan, M. Phelan, M. Mallinson, M.A. Norcross, Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions, J. Virol. 65:1543 (1991).

    PubMed  CAS  Google Scholar 

  107. D.I. Abrams, S. Kuno, R. Wong, et al., Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex, Ann. Intern. Med. 110:183 (1989).

    PubMed  CAS  Google Scholar 

  108. K. Lorentsen, C. Hendrix, J. Collins, R. Eckel, B. Petty, P. Lietman, Dextran sulfate is poorly absorbed after oral administration, Ann. Intern. Med. 111:561 (1989).

    PubMed  CAS  Google Scholar 

  109. N.R. Hartman, D.G. Johns, H. Mitsuya, Pharmacokinetic analysis of dextran sulfate in rats as pertaining to its clinical usefulness for therapy of HIV infection, AIDS Res. Human Retrovir. 6:805 (1990).

    Article  CAS  Google Scholar 

  110. M. Baba, E. De Clercq, S. Iida, et al., Anti-human immunodeficiency virus type 1 activities and pharmacokinetics of novel 6-substituted acyclouridine derivatives, Antimicrob. Agents Chemother. 34:2358 (1990).

    Article  PubMed  CAS  Google Scholar 

  111. M. Baba, E. De Clercq, D. Schols, et al., Novel sulfated polysaccharides: dissociation of anti-human immunodeficiency virus activity from antithrombin activity, J. Infect. Dis. 161:208 (1990).

    Article  PubMed  CAS  Google Scholar 

  112. A. Handa, H. Hoshino, K. Nakajima, et al., Inhibition of infection with human immunodeficiency virus type 1 by sulfated gangliosides, Biochem. Biophys. Res. Commun. 175:1 (1991).

    Article  PubMed  CAS  Google Scholar 

  113. T. Aoki, Y. Kaneko, M.S. Stefanski, T. Nguyen, R.C.Y. Ting, Curdlan sulfate and HIV-1.1. In vitro inhibitory effects of curdlan sulfate on HIY-1 infection, AIDS Res. Hum. Retrov. 7:409 (1991).

    Article  CAS  Google Scholar 

  114. P. Mohan, R. Singh, M. Baba, Potential anti-AIDS agents: Synthesis and antiviral activity of naphthalenesulfonic acid derivatives against HIY-1 and HIV-2, J. Med. Chem. 34:212 (1991).

    Article  PubMed  CAS  Google Scholar 

  115. M.A. Gama Sosa, F. Fazely, J.A. Koch, S.V. Vercellotti, R.M. Ruprecht, N-Carboxymethylchitosan-N,O-sulfate as an anti-HIV-1 agent, Biochem. Biophys. Res. Commun. 174:489 (1991).

    Article  CAS  Google Scholar 

  116. J.L. Weaver, P. Gergely, P.S. Pine, E. Patzer, A. Aszalos, Polyionic compounds selectively alter availability of CD4 receptors for HIV coat protein rgp 120, AIDS Res. Hum. Retrov. 6:1125 (1990).

    Article  CAS  Google Scholar 

  117. S. Nakamura, S. Sakurada, S.Z. Salahuddin, et al., Inhibition of development of Kaposi’s sarcoma-related lesions by a bacterial cell wall complex, Science 255:1437 (1992).

    Article  PubMed  CAS  Google Scholar 

  118. M. Nakamura, S. Kunimoto, Y. Takahashi, et al., Inhibitory effects of polyethers on human immunodeficiency virus replication, Antimicrob. Agents. Chemother. 36:492 (1992).

    Article  PubMed  CAS  Google Scholar 

  119. R. Pal, S. Mumbauer, G.M. Hoke, A. Takatsuki, M.G. Sarngadharan, Brefeldin A inhibits the processing and secretion of envelope glycoproteins of human immunodeficiency virus type 1, AIDS Res. Hum. Retrovir. 7:707 (1991).

    Article  PubMed  CAS  Google Scholar 

  120. S. Loya, R. Tal, Y. Kashman, A. Hizi, Illimaquinone, a selective inhibitor of the RNase H activity of human immunodeficiency virus type 1 reverse transcriptase, Antimicrob. Agents. Chemother. 34:2009 (1990).

    Article  PubMed  CAS  Google Scholar 

  121. J.F. Davies, Z. Hostomska, Z. Hostomsky, S.R. Jordan, D.A. Matthews, Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase, Science 252:88 (1991).

    Article  PubMed  CAS  Google Scholar 

  122. K. Moelling, T. Schulze, H. Diringer, Inhibition of human immunodeficiency virus type 1 RNase H by sulfated polyanions, J. Virol. 63:5489 (1989).

    PubMed  CAS  Google Scholar 

  123. A. De Giulio, S. De Rosa, G. Strazzullo, et al., Synthesis and evaluation of cytostatic and antiviral activityies of 3′ and 4′-avarone derivatives, Antiviral Chem. Chemother. 2:223 (1991).

    Google Scholar 

  124. D.H. Smith, R.A. Byrn, S.A. Marsters, T. Gregory, J.E. Groopman, D.J. Capon, Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen, Science 238:1704 (1987).

    Article  PubMed  CAS  Google Scholar 

  125. R. Fisher, J. Bertonis, W. Meier, et al., HIV infection is blocked in vitro by recombinant soluble CD4, Nature 331:76 (1988).

    Article  PubMed  CAS  Google Scholar 

  126. R. Hussey, N. Richardson, M. Kowalski, et al., A soluble CDr protein selectively inhibits HIV replication and syncytium formation, Nature 331:82 (1988).

    Article  Google Scholar 

  127. A. Traunecker, W. Lueke, K. Karjalainen, Soluble CD4 molecules neutralize human immunodeficiency virus type 1,. Nature 331:84 (1988).

    Article  PubMed  CAS  Google Scholar 

  128. M.A. Harbison, J.M. Gillis, P. Pinkston, R.A. Byrn, R.M. Rose, S.M. Hammer, Effects of recombinant soluble CD4(rCD4) on HIV-1 infection of monocyte/macrophages, J. Infect. Dis. 161:1 (1990).

    Article  PubMed  CAS  Google Scholar 

  129. J.P. Moore, R.A. Weiss, Passive primate protection, Nature 352 (1991), 376 (1 August 1991).

    Article  PubMed  CAS  Google Scholar 

  130. W.A. O’Brien, I.S.Y. Chen, D.D. Ho, E.S. Daar, Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4, J. Virol. 66:3125 (1992).

    CAS  Google Scholar 

  131. S.P. Layne, M.J. Merges, J.L. Spouge, M. Dembo, P.L. Nara, Blocking of human immunodeficiency virus infection depends on cell density and viral stock age, J. Virol. 65:3293 (1991).

    PubMed  CAS  Google Scholar 

  132. T.K. Hart, R. Kirsh, H. Ellens, et al., Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein GP120, Proc. Natl. Acad. Sci. USA 88:2189 (1991).

    Article  PubMed  CAS  Google Scholar 

  133. L. Dirckx, D. Lindemann, R. Ette, C. Manzoni, D. Moritz, J. Mous, Mutation of conserved N-glycosylation sites around the CD4-binding site of human immunodeficiency virus type 1 GP120 affects viral infectivity, Virus Res. 18:9 (1990).

    Article  PubMed  CAS  Google Scholar 

  134. P.S. Sarin, R.C. Gallo, D.I. Scheer, F. Crews, A.S. Lippa, Effects of a novel compound (AL 721) on HTLV-III infectivity in vitro, N. Engl. J. Med. 313:1289 (1985).

    Article  PubMed  CAS  Google Scholar 

  135. D. Mildvan, J. Buzas, D. Armstrong, et al., An open-label, dose ranging trial of AL721 in patients with persistent generalized lymphadenopathy and AIDS-related complex, J. Acquir. Immun. Defic. Syndr. 4:945 (1991).

    CAS  Google Scholar 

  136. K.R. Gustafson, J.H. Cardellina, R.W. Fuller, et al., AIDS-antiviral sulfolipids from cyanobacteria (blue-green algae), J. Natl. Cancer Inst. 81:1254 (1989).

    Article  PubMed  CAS  Google Scholar 

  137. A. Baur, T. Harrer, M. Peukert, G. Jahn, J.R. Kalden, B. Fleckenstein, Alpha-lipoic acid is an effective inhibitor of human immunodeficiency virus (HIV-1) replication, Klin. Wochenschr. 69:722–724 (1991).

    Article  PubMed  CAS  Google Scholar 

  138. J. Balzarini D. Schols, J. Neyts, E. Van Damme, W. Peumans, E. De Clercq, a-(1-3)-and a-(1-6)-D-Mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro, Antimicrob. Agents. Chemother. 35:410 (1991).

    Article  PubMed  CAS  Google Scholar 

  139. J.E.S. Hansen, C.M. Nielsen, C. Nielsen, P. Heegaard, L.R. Mathiesen, J.P. Nielsen, Correlation between carbohydrate structures on the envelope glycoprotein gp120 of HIV-1 and HIV-2 and syncytium inhibition with lectins, AIDS 3:635 (1989).

    Article  PubMed  CAS  Google Scholar 

  140. R.W. Jansen, G. Molema, R. Pauwels, D. Schols, E. De Clercq, D.K.F. Meijer, Potent in vitro anti-HIV activity of modified human serum albumins, Mol. Pharmacol. 39:818 (1991).

    PubMed  CAS  Google Scholar 

  141. G. Molema, R.W. Jansen, J. Visser, P. Herdewijn, F. Moolenaar, D.K.F. Meijer, Neoglycoproteins as carriers for antiviral drugs: synthesis and analysis of protein-drug conjugates, J. Med. Chem. 34:1137 (1991).

    Article  PubMed  CAS  Google Scholar 

  142. K. Ono, H. Nakane, M. Fukushima, J.C. Chermann, F. Barre-Sinoussi, Inhibition of reverse transcriptase activity by a flavonoid compound, 5,6,7-trihydroxyflavone, Biochem. Biophys. Res. Commun. 160:982 (1989).

    Article  PubMed  CAS  Google Scholar 

  143. M.L. Bryant, R.O. Heuckeroth, J.T. Kimata, L. Ratner, J.I. Gordon, Replication of human immunodeficiency virus 1 and Moloney murine leukemia virus is inhibited by different heteroatom-containing analogs of myristic acid, Proc. Natl. Acad. Sci. 86:8655 (1989).

    Article  PubMed  CAS  Google Scholar 

  144. R. Pal, R.C. Gallo, M.G. Sarngadharan, Processing of the structural proteins of human immunodificiency virus type 1 in the presence of monensin and cerulenin, Proc. Natl. Acad. Sci. USA 85:9283 (1989).

    Article  Google Scholar 

  145. J.J. Blumenstein, T.D. Copeland, S. Oroszlan, C.J. Michejda, Synthetic non-peptide inhibitors of HIV protease. Biochem Biophys Res Commun 163:980 (1989).

    Article  PubMed  CAS  Google Scholar 

  146. R. Buhl, H.A. Jaffe, K.J. Holroyd et al., Glutathione deficiency and HIV, Lancet 335:546 (1990).

    Article  PubMed  CAS  Google Scholar 

  147. A.L. Kinter, T. Kalebic, G. Poli, A.S. Fauci, Suppression of cytokine-induced human immunodeficiency virus (HIV) expression by N-acetyl-cystein (NAC), glutathione (GSH) and glutathione-monoester (GSE), FASEB Abstr II:A1265 (1991).

    Google Scholar 

  148. S.T. Butera, V.L. Perez, B-Y Wu, G J. Nabel, T.M. Folks, Oscillation of the human immunodeficiency virus surface receptor is regulated by the state of viral activation in a CD4+ cell model of chronic infection, J. Virol. 65:4645 (1991).

    PubMed  CAS  Google Scholar 

  149. P. Feorino, S. Butera, T.M. Folks, R.F. Schinazi, Antiviral agents that prevent reactivation of latent HIV-1 in OM 10.1 cells. National Collaborative Drug Discovery Group, Frontiers in HIV Therapy, San Diego, CA (Nov. 3–7, 1991).

    Google Scholar 

  150. M. Ito, M. Baba, S. Mori, et al., Tumor necrosis factor antagonizes inhibitory effect of azidothymidine on human immunodeficiency virus (HIV) replication in vitro, Biochem. Biophys. Res. Commun. 166:1095 (1990).

    Article  PubMed  CAS  Google Scholar 

  151. E. Tabor, J.S. Epstein, I.K. Hewlett, S.F. Lee, Inhibition by desferrioxamine of in-vitro replication of HIV-1, Lancet, 337:795 (March 30, 1991).

    Article  PubMed  CAS  Google Scholar 

  152. J.V. Lloyd, H. Cable, C. Rice-Evans, Evidence that desferrioxamine cannot enter cells by passive diffusion, Biochem. Pharmacol. 41:1361 (1991).

    Article  PubMed  CAS  Google Scholar 

  153. D.R.C. McLachlan, A.J. Dalton, T.P.A. Kruck, et al., Intramuscular desferrioxamine in patients with Alzheimer’s disease, Lancet 337:1304 (1991).

    Article  Google Scholar 

  154. G. Fredj, F. Dietlin, D. Fredj, et al., Tetrahydroaminoacridine in HIV infections, Int. J. Clin. Pharmacol. Ther. Toxicol. 27:408 (1989).

    PubMed  CAS  Google Scholar 

  155. D.D. Richman, Zidovudine resistance of human immunodeficiency virus, Rev. Infect. Dis. 12:S507 (1990).

    Article  PubMed  Google Scholar 

  156. S.M. Crowe, M.S. McGrath, T. Elbeik, J. Kirihara, J. Mills, Comparative assessment of antiretrovirals in human monocyte-macrophages and lymphoid cell lines acutely and chronically infected with the human immunodeficiency virus, J. Med. Virol. 29:S145 (1989).

    Article  Google Scholar 

  157. R. Yarchoan, J.M. Pulda, C.F. Perno, H. Mitsuya, S. Broder, Antiretroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future, Blood 78:859 (1991).

    PubMed  CAS  Google Scholar 

  158. S.G. Ayre, New approaches to the delivery of drugs to the brain, Med. Hypoth. 29:283 (1989).

    Article  CAS  Google Scholar 

  159. R.F. Schinazi, Strategies and targets for anti-human immunodeficiency virus type 1 chemotherapy, in: “AIDS in Children, Adolescents and Heterosexual Adults: An Interdisciplinary Approach to Prevention,” R.F. Schinazi, A.J. Nahmias, eds., Elsevier, New York, 126 (1988).

    Google Scholar 

  160. R.F. Schinazi, C.K. Chu, B.F. Eriksson, et al., Antiretroviral activity, biochemistry, and pharmacokinetics of 3′-azido-2′,3′-dideoxy-5-methylcytidine, Ann. NY Acad. Sci. 616:385 (1990).

    Article  PubMed  CAS  Google Scholar 

  161. F.C. Szoka, The future of liposomal drug delivery, Biotechnol. Appl. Biochem. 12:496 (1990).

    PubMed  CAS  Google Scholar 

  162. X. Lin, A. Dashti, R.F. Schinazi, J. Tang, Intracellular diversion of envelope glycoprotein gp 160 of human immunodeficiency virus to lysosomes for degradation, American Society for Biochemistry and Molecular Biology/Biophysical Society Houston, TX (February 9–13, 1992).

    Google Scholar 

  163. B.E. Huber, C.A. Richards, T.A. Krenitsky, Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy, Proc. Natl. Acad. Sci. USA 88:8039 (1991).

    Article  PubMed  CAS  Google Scholar 

  164. W. James, Towards gene-inhibition therapy: a review of progress and prospects in the field of antiviral antisense nucleic acids and ribozymes, Antiviral Chem. Chemother. 2:191 (1991).

    CAS  Google Scholar 

  165. J.A.T. Young, P. Bates, K. Willert, H.E. Varmus, Efficient incorporation of human CD4 protein into avian leukosis virus particles, Science 250:1421 (1990).

    Article  PubMed  CAS  Google Scholar 

  166. R.F. Schinazi, D.C. Liotta, W.B. Choi, et al., Selective inhibition of human immunodeficiency virus and hepatitis B virus by 2′,3′-dideoxy-5-fluoro-3′-thiacytidine (FTC), National Collaborative Drug Discovery Group, Frontiers in HIV Therapy, San Diego, CA (Nov. 3–7, 1991).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, 30322, USA

    Raymond F. Schinazi

  2. Veterans Affairs Medical Center, Decatur, Georgia, 30033, USA

    Raymond F. Schinazi

Authors
  1. Raymond F. Schinazi
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The University of Georgia, Athens, Georgia, USA

    Chung K. Chu

  2. Agricultural Research Service, United States Department of Agriculture, Athens, Georgia, USA

    Horace G. Cutler

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer Science+Business Media New York

About this chapter

Cite this chapter

Schinazi, R.F. (1992). Progress in the Development Of Natural Products for Human Immunodeficiency Viruses Infections. In: Chu, C.K., Cutler, H.G. (eds) Natural Products as Antiviral Agents. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3414-3_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3414-3_1

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6509-9

  • Online ISBN: 978-1-4615-3414-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation